D3250R00107 – BURAN: Effects of Benralizumab in Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters
Status: Ongoing
Details
The aim of this study is to learn more about the drug called benralizumab (Fasenra®)
and to better understand how it works in the treatment of severe eosinophilic asthma.
Sponsor: AstraZeneca
NCT05552508 - IRB#2022-107